Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Affiliated Hospital of Zunyi Medical University is a company patent portfolio with 3 pending office actions. These actions are situated within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters is handled by 3 distinct examiners, which indicates that each pending action is being reviewed by a different individual. This distribution shows that the portfolio's current workload is not concentrated under a single examiner.
The data reveals that there are 3 distinct art units involved in these cases. This means that the Biotechnology & Pharmaceuticals filings are spread across 3 different technical examination groups. For a practitioner, this distribution across 3 distinct art units and 3 distinct examiners suggests that the portfolio is subject to a variety of technical perspectives and administrative styles within the patent office.
KOSTURKO, GEORGE W is the busiest examiner for this portfolio, with 1 pending office action. This 1 pending action for the busiest examiner is a portion of the 3 total pending office actions for the university. Because each of the 3 distinct examiners is handling a different matter, no single examiner holds a majority of the workload. The prosecution strategy must therefore account for the specific requirements of 3 different art units and their respective examiners.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSTURKO, GEORGE W | 1 | 54.6% | +49.0% |
| ADLAM, CHANTAL PETA-GAYE | 1 | 53.5% | +27.8% |
| CLARK, AMY LYNN | 1 | 39.2% | +31.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18462388 | APPLICATION OF CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING AND/OR PREVENTING LIVER FIBROSIS | ADLAM, CHANTAL PETA-GAYE | 16d |
| 18348332 | APPLICATION METHOD OF POTASSIUM ION CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING LIVER FIBROSIS | CLARK, AMY LYNN | 27d |
| 18467687 | APPLICATION OF ION CHANNEL BLOCKER IN TREATMENT AND/OR PREVENTION OF HEPATIC FIBROSIS | KOSTURKO, GEORGE W | 42d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18462388 | APPLICATION OF CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING AND/OR PREVENTING LIVER FIBROSIS | ADLAM, CHANTAL PETA-GAYE | 16d |
| 18348332 | APPLICATION METHOD OF POTASSIUM ION CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING LIVER FIBROSIS | CLARK, AMY LYNN | 27d |
| 18467687 | APPLICATION OF ION CHANNEL BLOCKER IN TREATMENT AND/OR PREVENTION OF HEPATIC FIBROSIS | KOSTURKO, GEORGE W | 42d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1622 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18467687 | APPLICATION OF ION CHANNEL BLOCKER IN TREATMENT AND/OR PREVENTION OF HEPATIC FIBROSIS | KOSTURKO, GEORGE W | 1621 | §103§112 | Final Rejection | 42d | Pending | Sep 14, 2023 |
| 18462388 | APPLICATION OF CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING AND/OR PREVENTING LIVER FIBROSIS | ADLAM, CHANTAL PETA-GAYE | 1622 | §103§112 | Final Rejection | 16d | Pending | Sep 06, 2023 |
| 18348332 | APPLICATION METHOD OF POTASSIUM ION CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING LIVER FIBROSIS | CLARK, AMY LYNN | 1628 | §103§112 | Non-Final OA | 27d | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAffiliated Hospital of Zunyi Medical University has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
George W Kosturko has the most, with 1 of Affiliated Hospital of Zunyi Medical University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
